Get the Stockscreener App
207.80
0.83%
-1.74
After Hours:
207.80
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $207.80, with a volume of 798.31K.
It is down -0.83% in the last 24 hours and up +14.79% over the past month.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$209.54
Open:
$209.52
24h Volume:
798.31K
Relative Volume:
0.76
Market Cap:
$22.91B
Revenue:
$10.52B
Net Income/Loss:
$999.00M
P/E Ratio:
24.85
EPS:
8.3628
Net Cash Flow:
$1.22B
1W Performance:
+1.67%
1M Performance:
+14.79%
6M Performance:
+16.31%
1Y Performance:
+18.47%
1-Day Range:
$206.13
$210.69
1-Week Range:
$200.94
$210.69
52-Week Range:
$157.20
$213.20
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
207.80 | 23.10B | 10.52B | 999.00M | 1.22B | 8.3628 |
|
TMO
Thermo Fisher Scientific Inc
|
513.68 | 193.72B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
209.52 | 147.88B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
657.38 | 51.84B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
124.72 | 35.19B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.44 | 32.01B | 3.17B | 642.63M | 516.49M | 10.77 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-25-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-02-25 | Initiated | Redburn Atlantic | Buy |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
Quest Diagnostics to Speak at the Leerink 2026 Global Healthcare Conference - PR Newswire
Quest Diagnostics (NYSE:DGX) EVP Sells $293,521.39 in Stock - Defense World
Compass Wealth Management LLC Makes New Investment in Quest Diagnostics Incorporated $DGX - Defense World
ANTIPODES PARTNERS Ltd Has $11.76 Million Position in Quest Diagnostics Incorporated $DGX - Defense World
Quest Diagnostics (NYSE:DGX) SVP Sells $196,227.14 in Stock - MarketBeat
Insider Selling: Quest Diagnostics (NYSE:DGX) SVP Sells 1,111 Shares of Stock - MarketBeat
A diagnostics company moved out. Its former landlord claims it left a mess. - The Business Journals
Quest Diagnostics Incorporated $DGX Stock Holdings Boosted by Vanguard Group Inc. - MarketBeat
First National Bank of Omaha Invests $8.83 Million in Quest Diagnostics Incorporated $DGX - MarketBeat
Advisors Capital Management LLC Acquires 14,258 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Skandinaviska Enskilda Banken AB publ Sells 27,243 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Piper Sandler Adjusts Price Target on Quest Diagnostics to $215 From $200, Maintains Neutral Rating - marketscreener.com
Do Wall Street Analysts Like Quest Diagnostics Stock? - Barchart.com
Labcorp forecasts upbeat annual profit on strong demand for diagnostic products - Reuters
5 Insightful Analyst Questions From Quest's Q4 Earnings Call - Finviz
Cibc World Market Inc. Increases Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
M&G PLC Has $208.26 Million Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Sold by Advisors Asset Management Inc. - Defense World
Quest Diagnostics Incorporated $DGX Shares Sold by ABN Amro Investment Solutions - MarketBeat
Rhumbline Advisers Decreases Stock Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
ING Groep NV Makes New Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
Wall Street Recap: What analysts say about Quest Diagnostics Incorporated stock - baoquankhu1.vn
A Look At Quest Diagnostics (DGX) Valuation After Strong Results, 2026 Outlook, Buybacks And New Myeloma Test - Yahoo Finance
Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.86 - Yahoo Finance
Quest Diagnostics Incorporated $DGX Shares Sold by Cookson Peirce & Co. Inc. - MarketBeat
Quest Diagnostics (DGX): Analyst Raises Price Target to $235 | D - GuruFocus
Mizuho Securities Adjusts Quest Diagnostics PT to $235 From $210, Maintains Outperform Rating - marketscreener.com
Rothschild & Co Redburn Adjusts Quest Diagnostics PT to $224 From $200, Maintains Buy Rating - marketscreener.com
Forecasting The Future: 6 Analyst Projections For Quest Diagnostics - Benzinga
DGX Q4 Deep Dive: Consumer Testing and Advanced Diagnostics Fuel Growth Amid Margin Headwinds - Finviz
Quest Diagnostics (DGX): Truist Securities Raises Price Target A - GuruFocus
UBS Raises Price Target for Quest Diagnostics (DGX) to $210 | DG - GuruFocus
Deutsche Bank Adjusts Quest Diagnostics Price Target to $205 From $178, Maintains Hold Rating - marketscreener.com
DGX: Evercore ISI Group Raises Price Target for Quest Diagnostics | DGX Stock News - GuruFocus
Quest Diagnostics (DGX): Navigating the New Frontier of Advanced Diagnostics and AI Efficiency - FinancialContent
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Evercore ISI Adjusts Quest Diagnostics PT to $220 From $190, Maintains In Line Rating - marketscreener.com
Barclays Adjusts Quest Diagnostics PT to $225 From $210, Maintains Overweight Rating - marketscreener.com
Baird Adjusts Quest Diagnostics Price Target to $219 From $203, Maintains Neutral Rating - marketscreener.com
Quest Diagnostics Incorporated (NYSE:DGX) Q4 2025 Earnings Call Transcript - Insider Monkey
DGX: Jefferies Raises Target Price for Quest Diagnostics to $220 - GuruFocus
Truist Raises Price Target on Quest Diagnostics to $220 From $205, Keeps Hold Rating - marketscreener.com
Candriam S.C.A. Has $13.69 Million Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Shares Jump on Q4 Beat; FY25 Revenue Rises, 2026 Outlook Raised - AlphaStreet News
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MSN
Quest Diagnostics Q4 Earnings Call Highlights - Yahoo Finance
Jefferies Maintains Buy on Quest Diagnostics (DGX) Feb 10, 2026 - Meyka
Quest Diagnostics: Q4 Earnings Snapshot - theheraldreview.com
Why Is Quest (DGX) Stock Soaring Today - Finviz
Quest Diagnostics (DGX) Earnings Call Transcript - The Globe and Mail
Quest Diagnostics Inc (DGX) Q4 2025 Earnings Call Highlights: St - GuruFocus
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):